UY25557A1 - Combinaciones terapeúticas para la fragilidad musculoesquelética - Google Patents
Combinaciones terapeúticas para la fragilidad musculoesqueléticaInfo
- Publication number
- UY25557A1 UY25557A1 UY25557A UY25557A UY25557A1 UY 25557 A1 UY25557 A1 UY 25557A1 UY 25557 A UY25557 A UY 25557A UY 25557 A UY25557 A UY 25557A UY 25557 A1 UY25557 A1 UY 25557A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compositions
- fragility
- pyridin
- oxo
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta invención se refiere a composiciones de combinación farmacéutica y procedimientos, que comprenden (-)-cis-6-fenil-5-(4-(2-pirrolidin-1-il-etoxi)-fenil)-5,6,7,8-tetrahidronaftaleno-2-ol o una sal farmacéuticamente aceptable del mismo y 2-amino-N-(1(R)-(2,4-difluoro-benciloximetil)-2-oxo-2-(3-oxo-3a(R)-piridin-2-ilmetil)-2-(2,2,2-trifluoro-etil)-2,3,3a,4,6,7-hexahidrapirazolo[4,3,c]piridin-5-il)-etil)-2-metil-propionamida o una sal farmacéuticamente aceptable de la misma, a procedimientos de uso de tales composiciones y a estuches que contienen tales composiciones. Las composiciones son útiles para el tratamiento de la fragilidad musculoesquelética, incluyendo la osteoporosis, fracturas osteoporóticas, reducción de masa ósea, fragilidad y reducción de masa muscular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942498P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25557A1 true UY25557A1 (es) | 2001-01-31 |
Family
ID=22217565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25557A UY25557A1 (es) | 1998-06-16 | 1999-06-11 | Combinaciones terapeúticas para la fragilidad musculoesquelética |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1085867A1 (es) |
| JP (1) | JP2002518328A (es) |
| KR (1) | KR20010052817A (es) |
| CN (1) | CN1305378A (es) |
| AP (1) | AP9901581A0 (es) |
| AR (1) | AR018868A1 (es) |
| AU (1) | AU3342099A (es) |
| BG (1) | BG105128A (es) |
| BR (1) | BR9911357A (es) |
| CA (1) | CA2335112A1 (es) |
| CO (1) | CO5070586A1 (es) |
| EA (1) | EA200001189A1 (es) |
| GT (1) | GT199900083A (es) |
| HR (1) | HRP20000857A2 (es) |
| HU (1) | HUP0102395A2 (es) |
| ID (1) | ID26726A (es) |
| IL (1) | IL139587A0 (es) |
| IS (1) | IS5727A (es) |
| MA (1) | MA26648A1 (es) |
| NO (1) | NO20006381D0 (es) |
| OA (1) | OA11569A (es) |
| PA (1) | PA8472101A1 (es) |
| PE (1) | PE20000633A1 (es) |
| PL (1) | PL345064A1 (es) |
| SK (1) | SK18902000A3 (es) |
| TN (1) | TNSN99118A1 (es) |
| UY (1) | UY25557A1 (es) |
| WO (1) | WO1999065488A1 (es) |
| ZA (1) | ZA993973B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| CA2420535A1 (en) * | 2000-08-30 | 2002-03-07 | Mary Tanya Am Ende | Sustained release formulations for growth hormone secretagogues |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| DK1460969T3 (da) * | 2001-11-29 | 2008-09-01 | Gtx Inc | Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| EP2118080B1 (en) | 2007-02-09 | 2016-08-31 | Ocera Therapeutics, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1999
- 1999-05-03 EP EP99914723A patent/EP1085867A1/en not_active Withdrawn
- 1999-05-03 CN CN99807381A patent/CN1305378A/zh active Pending
- 1999-05-03 HU HU0102395A patent/HUP0102395A2/hu unknown
- 1999-05-03 ID IDW20002604A patent/ID26726A/id unknown
- 1999-05-03 OA OA1200000346A patent/OA11569A/en unknown
- 1999-05-03 JP JP2000554368A patent/JP2002518328A/ja active Pending
- 1999-05-03 KR KR1020007014140A patent/KR20010052817A/ko not_active Application Discontinuation
- 1999-05-03 EA EA200001189A patent/EA200001189A1/ru unknown
- 1999-05-03 AU AU33420/99A patent/AU3342099A/en not_active Abandoned
- 1999-05-03 PL PL99345064A patent/PL345064A1/xx unknown
- 1999-05-03 BR BR9911357-0A patent/BR9911357A/pt not_active Application Discontinuation
- 1999-05-03 IL IL13958799A patent/IL139587A0/xx unknown
- 1999-05-03 SK SK1890-2000A patent/SK18902000A3/sk unknown
- 1999-05-03 CA CA002335112A patent/CA2335112A1/en not_active Abandoned
- 1999-05-03 WO PCT/IB1999/000796 patent/WO1999065488A1/en not_active Application Discontinuation
- 1999-05-07 PA PA19998472101A patent/PA8472101A1/es unknown
- 1999-06-10 AP APAP/P/1999/001581A patent/AP9901581A0/en unknown
- 1999-06-11 PE PE1999000522A patent/PE20000633A1/es not_active Application Discontinuation
- 1999-06-11 UY UY25557A patent/UY25557A1/es not_active Application Discontinuation
- 1999-06-14 GT GT199900083A patent/GT199900083A/es unknown
- 1999-06-15 AR ARP990102847A patent/AR018868A1/es not_active Application Discontinuation
- 1999-06-15 ZA ZA9903973A patent/ZA993973B/xx unknown
- 1999-06-15 MA MA25622A patent/MA26648A1/fr unknown
- 1999-06-15 TN TNTNSN99118A patent/TNSN99118A1/fr unknown
- 1999-06-16 CO CO99037624A patent/CO5070586A1/es unknown
-
2000
- 2000-11-24 IS IS5727A patent/IS5727A/is unknown
- 2000-12-14 HR HR20000857A patent/HRP20000857A2/hr not_active Application Discontinuation
- 2000-12-14 NO NO20006381A patent/NO20006381D0/no not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105128A patent/BG105128A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP9901581A0 (en) | 1999-06-30 |
| CN1305378A (zh) | 2001-07-25 |
| EP1085867A1 (en) | 2001-03-28 |
| CO5070586A1 (es) | 2001-08-28 |
| BR9911357A (pt) | 2001-03-13 |
| HUP0102395A2 (hu) | 2001-11-28 |
| AR018868A1 (es) | 2001-12-12 |
| AU3342099A (en) | 2000-01-05 |
| ID26726A (id) | 2001-02-01 |
| PE20000633A1 (es) | 2000-07-26 |
| HRP20000857A2 (en) | 2001-10-31 |
| OA11569A (en) | 2004-07-01 |
| IL139587A0 (en) | 2002-02-10 |
| EA200001189A1 (ru) | 2001-06-25 |
| NO20006381L (no) | 2000-12-14 |
| PL345064A1 (en) | 2001-11-19 |
| CA2335112A1 (en) | 1999-12-23 |
| GT199900083A (es) | 2000-12-05 |
| PA8472101A1 (es) | 2000-09-29 |
| JP2002518328A (ja) | 2002-06-25 |
| TNSN99118A1 (fr) | 2005-11-10 |
| SK18902000A3 (sk) | 2001-12-03 |
| KR20010052817A (ko) | 2001-06-25 |
| WO1999065488A1 (en) | 1999-12-23 |
| BG105128A (en) | 2001-11-30 |
| IS5727A (is) | 2000-11-24 |
| ZA993973B (en) | 2000-12-15 |
| MA26648A1 (fr) | 2004-12-20 |
| NO20006381D0 (no) | 2000-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1222195E (pt) | Novos compostos de tiazolo(4,5-d)pirimidina | |
| EA200400735A1 (ru) | 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ | |
| BG111017A (bg) | Нови кристални и аморфна форми на съединението триазоло (4, 5- d)пиримидин | |
| EE04018B1 (et) | Tieno[2,3-d]pürimidiindioonid, nende valmistamisemeetod ja neid sisaldavad ravimkoostised | |
| RU94013439A (ru) | Гетероциклические соединения, способ их получения, фармацевтическая композиция и способ лечения | |
| HUP0402270A2 (hu) | [1,2,4]Triazolo[1,5-c]pirimidin-5-il-aminok mint adenozin A2a receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények | |
| UY25557A1 (es) | Combinaciones terapeúticas para la fragilidad musculoesquelética | |
| BR9911228A (pt) | Combinações terapêuticas compreendendo um modulador seletivo de um receptor de estrogênio e hormÈnio paratireóide | |
| SE0002729D0 (sv) | Novel compound form | |
| AR018869A1 (es) | Composicion farmaceutica, su uso para la preparacion de medicamentos y estuche que la contiene | |
| ECSP993021A (es) | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
| ECSP993020A (es) | Terapia de combinacion para la fragilidad musculoesqueletica | |
| HUP0002643A2 (hu) | Szívrendellenességek kezelése és megelőzése SSRI-k alkalmazásával | |
| SE0100296D0 (sv) | New compounds | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| SE0100295D0 (sv) | New compounds | |
| HA et al. | A Study on Osteoarthrosis in Korean Young Women Volley Ball Players | |
| TH48282A (th) | การรักษาโรคของการให้ยาประกอบร่วมกันของโรคกระดูกพรุน | |
| DE69318418T2 (de) | Pharmazeutische zusammensetzungen, die 5-ht 1-rezeptoragonisten und absorptionsverstärker enthalten | |
| AR015307A1 (es) | Formas cristalinas de monoclorhidrato de pirazinas, composiciones, metodo de tratamiento que las utiliza y metodo de preparacion de dichas formas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20110408 |